CD274 and neoplasm: Recent research verified that co-administration of BJIKT with the anti-PD-L1 antibody significantly improved T-cell response in the MC38 tumor-bearing mouse model, highlighting its potential therapeutic viability for cancer treatment (Chun et al., 2022).